1. 826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. (23rd October 2018) Authors: Sternberg, C N; Tombal, B; Miller, K; Saad, F; Sartor, O; Sade, J P; Logothetis, C; Bellmunt, J; Dizdarevic, S; Harshman, L C; Logue, J; Baldari, S; Richardson, T; Bottomley, D; Schostak, M; Bayh, I; Kalinovsky, J; Higano, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗